证券代码：300584 证券简称：海辰药业 公告编号：2025-048 剂型：注射剂 规格：50ml:12.5g 注册分类：化学药品 3 类 上市许可持有人：南京海辰药业股份有限公司 南京海辰药业股份有限公司 关于公司硫代硫酸钠注射液获得药品注册批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"海辰药业"或"公司"）于近日 收到国家药品监督管理局（以下简称"国家药监局"）核准签发的《药品注册 证书》，现将相关情况公告如下： 一、药品的基本情况 药品名称：硫代硫酸钠注射液 上市许可持有人地址：南京经济技术开发区恒发路 1 号 生产企业：江苏悦兴药业有限公司 生产企业地址：江苏省兴化市南环路 29 号 证书编号：2025S02803 二、药品的其他情况 药品批准文号：国药准字 H20255403 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规 范要求方可生产销售。 ...

Group 1 - The company plans to participate in the October solid-state battery conference in Hefei [2] - An investor inquired about the company's participation in recent exhibitions related to battery materials [2] - The company confirmed its attendance at the Hefei solid-state battery conference on September 17 [2]

格隆汇9月16日丨海辰药业(300584.SZ)在投资者互动平台表示，公司在固态电池材料领域的相关项目尚 处于中试及小试阶段，具体进展可参见公司半年度报告。 ...

资料显示，南京海辰药业股份有限公司位于江苏省南京经济技术开发区恒发路1号，成立日期2003年1月 15日，上市日期2017年1月12日，公司主营业务涉及化学制剂、原料药及中间体的研发、生产、销售。 主营业务收入构成为：心脑血管类87.12%，抗生素类5.69%，原料药及中间体1.68%，消化类1.50%，抗 病毒类1.47%，其他(补充)0.83%，免疫调节类0.80%，其他类0.57%，利尿类0.34%。 海辰药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：固态电池、锂电池、仿 制药、创新药、生物医药等。 截至9月10日，海辰药业股东户数2.18万，较上期增加10.57%；人均流通股3773股，较上期减少9.56%。 2025年1月-6月，海辰药业实现营业收入3.09亿元，同比增长30.46%；归母净利润2915.77万元，同比增 长17.87%。 分红方面，海辰药业A股上市后累计派现1.61亿元。近三年，累计派现1800.00万元。 9月15日，海辰药业盘中下跌2.01%，截至10:48，报66.29元/股，成交4.06亿元，换手率7.33%，总市值 79.55亿元。 资金流向方面，主 ...

Investment Rating - The industry rating is optimistic [2] Core Insights - Solid-state batteries are expected to achieve a technological breakthrough in electrolyte technology by 2027 and may reach industrialization by 2030, with sulfide solid-state batteries being the most emphasized route domestically and internationally [3][24] - The current focus is on sulfide electrolytes, while composite electrolytes are anticipated to be the best long-term solution [4][33] - High-nickel ternary materials and silicon-carbon anodes are expected to dominate in the short term, with lithium-rich manganese-based and lithium metal anodes being the long-term goals [5][56] - Nickel-coated or nickel-based current collectors are being developed to address corrosion issues, while porous copper foils are being explored for their lightweight and elastic properties [6] - Other materials such as single-walled carbon nanotubes and UV adhesives are also gaining attention for their potential in solid-state battery applications [7] Summary by Sections Solid-State Battery Overview - Solid-state batteries are considered the ultimate form of lithium batteries, balancing safety and energy density [16][18] - The timeline for achieving significant milestones includes 200-300 Wh/kg energy density by 2027 and 400 Wh/kg by 2030 [19][24] Electrolytes - Sulfide electrolytes are currently the focus, with challenges in cost reduction and production scalability [4][39] - The development of halide electrolytes is also being pursued to enhance electrochemical stability and compatibility with high-voltage cathodes [44] Cathode Materials - High-nickel ternary materials are expected to be the primary choice for solid-state batteries, with ongoing modifications to improve performance [45][50] - Lithium-rich manganese-based materials are being developed to enhance energy density and reduce costs [55] Anode Materials - CVD silicon-carbon anodes are emerging as a leading option due to their performance and cost advantages, with significant growth expected in the coming years [61] - Lithium metal anodes are viewed as the ultimate solution, with ongoing research to address associated challenges [64] Investment Recommendations - Focus on leading companies in various material segments, including sulfide electrolytes, high-nickel ternary cathodes, CVD silicon-carbon anodes, and nickel-based current collectors [8]

Market Overview - A-shares experienced slight fluctuations with major indices like the Shenzhen Component Index, CSI 300, and STAR 50 reaching new highs, while the ChiNext Index surpassed 2900 points [1] - The market saw more gainers than losers, with stable trading volume [1] Sector Performance - The Shanghai Composite Index closed at 3862.65, up by 0.12%, while the Shenzhen Component Index rose to 12710.24, up by 0.11%. The ChiNext Index increased by 0.55% to 2906.03 [2] - Sectors such as gold, pharmaceuticals, advertising, and general retail showed significant gains, while aerospace equipment, glass fiber, insurance, and wind power equipment faced declines [2] Gold Market Dynamics - Gold prices surged, leading to a collective rise in gold stocks, with the sector index increasing over 4% to reach a historical high. Trading volume approached the previous day's total within just half a day [3] - International spot gold prices saw a substantial increase, with domestic gold futures also rising significantly, surpassing 800 yuan per contract, marking a two-and-a-half-month high [4] Geopolitical Influences - Rising geopolitical tensions, including attacks on Russian oil export terminals and ongoing conflicts in Gaza, have heightened risk aversion, boosting gold's appeal as a safe-haven asset [5] - Concerns over global economic slowdown were exacerbated by the U.S. imposing a 50% tariff on Indian goods, further enhancing gold's attractiveness [5] Pharmaceutical Sector Activity - The pharmaceutical and biotechnology sector rebounded, with sub-sectors like chemical drugs, innovative drugs, and weight-loss drugs collectively rising over 2%. Companies like Hai Chen Pharmaceutical and Yi Pin Hong saw significant stock price increases [6] - Hong Kong's pharmaceutical stocks also performed strongly, with indices like the Hong Kong Stock Connect Innovative Drug Index rising over 4% [9] Fund Activity in Pharmaceuticals - A significant number of pharmaceutical companies reported revenue growth in their semi-annual reports, with 67 out of over 100 companies achieving year-on-year revenue increases [11] - Prominent fund managers have increased their holdings in pharmaceutical stocks, indicating a bullish outlook for the sector [12]

Group 1 - The innovative drug sector is experiencing active trading, with companies like Maiwei Bio reaching a 20% limit up and others like Yipin Hong and Zhixiang Jintai seeing over 10% gains [1] - The innovative drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [1] - The adjustment of the medical insurance catalog will include commercial insurance for innovative drugs for the first time, indicating a positive trend for the sector [1] Group 2 - According to CICC, domestic engineer dividends, abundant clinical resources, and supportive policies are contributing to the transition of domestic innovative drugs from following to FIC and BIC innovation [1] - The innovative drug industry is entering a 2.0 era, having completed qualitative improvements, with strong pipeline data and ongoing large BD transactions [1] - The upcoming ESMO conference in mid-October is expected to bring new investment opportunities for the sector based on clinical data releases and BD activities [1] Group 3 - Since 2025, policies related to commercial health insurance have been continuously promoted, which is expected to accelerate payment reform in the medical system and support domestic innovation [2] - Recent policies on childcare subsidies are anticipated to alleviate long-term population pressures and stimulate consumption related to infants and young children [2] - With the increase in fiscal policies, domestic medical equipment-related stocks are also gaining market attention [2]

Group 1 - The solid-state battery concept continues to gain strength, with companies such as Shanghai Xiba, Hanke Technology, Guoxuan High-Tech, Dexin Technology, Beijing Lier, and Dinglong Technology reaching their daily limit increase [1] - Other companies like Xiandai Intelligent, Haichen Pharmaceutical, Jiao Cheng Ultrasound, Naconoer, Jinlongyu, and Liyuanheng also experienced significant gains [1]

Market Performance - The solid-state battery sector in the A-share market experienced a significant surge, with companies like XianDao Intelligent, Hangke Technology, and JieBang Technology hitting the 20% daily limit increase [1] - Other notable performers included HaiBo SiChuang nearing the limit, BeiTeRui rising by 17%, and NingDe Times increasing by over 11% [1] Company Financials - XianDao Intelligent reported a revenue of 6.61 billion yuan for the first half of 2025, marking a year-on-year growth of 14.92%, with a net profit of 740 million yuan, up 61.19% [1] - The operating cash flow for XianDao Intelligent reached 2.353 billion yuan, a substantial increase of 231.33% compared to the same period last year [1] - The lithium battery intelligent equipment segment generated 4.545 billion yuan in revenue, reflecting a year-on-year growth of 16.40% [1] Business Segments - Non-lithium business, particularly in photovoltaic intelligent equipment, achieved a revenue of 531 million yuan, up 32.04%, with its revenue share increasing to 8.04% [1] - XianDao Intelligent's overseas business continued to grow, with revenue reaching 1.154 billion yuan, a year-on-year increase of 5.42%, and a gross margin improvement to 40.27% [1] Stock Performance - XianDao Intelligent's stock rose by 20.01%, with a total market capitalization of 55.6 billion yuan and a year-to-date increase of 77.80% [2] - Other companies in the sector also saw significant stock price increases, with Hangke Technology and JieBang Technology both rising by 20% [2]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]